A personalized mRNA cancer vaccine combined with immunotherapy reduced the risk of recurrence or death by 42% in patients with high-risk melanoma following surgery, according to results from the phase 3 INTerpath-001 trial presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 24.
The vaccine, intismeran autogene, developed by Moderna and Merck, was administered alongside pembrolizumab, an anti-PD-1 immune checkpoint inhibitor used as adjuvant treatment for melanoma. The trial randomly assigned 1,137 adults with resected stage IIB–IV cutaneous melanoma to receive pembrolizumab plus intismeran or pembrolizumab plus placebo.
After a median follow-up of 24.6 months, the combination reduced the risk of recurrence or death by 42% compared with pembrolizumab alone (hazard ratio [HR] 0.58; 95% confidence interval [CI] 0.45–0.75). At two years, 82.2% of patients receiving the combination were alive without recurrence, compared with 70.0% of patients receiving pembrolizumab alone. The combination also reduced the risk of distant metastasis or death by 38%.
Tumor sequencing guides individualized vaccine design
Unlike conventional vaccines that target shared antigens, intismeran is designed around the molecular characteristics of an individual patient's tumor. Tumor sequencing identifies mutations that produce neoantigens—abnormal proteins that can help distinguish cancer cells from healthy cells. The vaccine encodes up to 34 selected neoantigens in messenger RNA (mRNA), instructing cells to produce the target proteins and stimulate an immune response against cancer.
“This is the first phase 3 study to show that a treatment built from the unique ‘fingerprint’ of a patient’s own tumor can reduce the risk of recurrence or death from cancer,” said lead author Georgina Long, PhD, MBBS, of the Melanoma Institute Australia and The University of Sydney in a press release.
The approach builds on research into personalized cancer vaccines and the mRNA technology used in COVID-19 vaccines. However, the precise mechanisms underlying the clinical benefit remain under investigation.
In a recent Science News article, oncologist and cancer immunotherapy researcher Suzanne Topalian, MD, of Johns Hopkins University described the findings as encouraging but cautioned that questions remain about how the vaccine works. Researchers have questioned whether the neoantigens encoded in the vaccine account for the benefit or whether other components of the mRNA platform, including its lipid nanoparticle delivery system, may contribute. The phase 3 trial's control group received placebo injections rather than a sham mRNA vaccine, limiting the ability to distinguish these possibilities.
Survival benefit and clinical adoption remain uncertain
Although recurrence-free outcomes improved, overall survival data were immature at the interim analysis. The study did not demonstrate a statistically significant difference in overall survival between the groups (HR 0.77; 95% CI 0.45–1.31). Longer follow-up will be needed to determine whether delaying recurrence translates into longer survival.
Grade 3 or higher adverse events occurred in 23.6% of patients receiving intismeran plus pembrolizumab and 20.3% receiving pembrolizumab alone. Fever was reported in 52.2% of patients receiving the combination, compared with 8.2% in the control group. Injection-site pain occurred in 51.0% versus 9.5%, while fatigue occurred in 38.5% versus 29.7%.
According to Science News, Moderna and Merck plan to seek US approval for the vaccine, but its potential clinical use raises questions about cost, manufacturing time, and patient selection. Each personalized dose takes approximately six weeks to produce, which could affect how quickly patients receive treatment.
Researchers have also raised questions about how its benefits compare with alternative immunotherapy strategies, including approaches that administer checkpoint inhibitors both before and after surgery.
“For a patient, more time free of melanoma is a meaningful benefit in its own right,” Long said. “Longer follow-up is needed to show an impact on melanoma-specific and overall survival, as well as whether the early benefit we are seeing across stages and subgroups holds, and which patients benefit most.”
Further trials are investigating personalized neoantigen vaccine approaches in additional cancers, including lung, bladder, kidney, and pancreatic cancer. However, results in melanoma do not establish that the approach will be effective across other tumor types.
For medical laboratory scientists, the findings highlight the potential clinical importance of tumor sequencing in personalized oncology. They also underscore the need for validated molecular workflows that can identify relevant tumor mutations and support the development of individualized therapies as this field advances.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.






